SEC Form 4 · accession 0001127602-16-049647
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — EVP, Corp & Med Affairs
Period of report
Apr 19, 2016
Accepted (ET)
Apr 21, 2016 · 1:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 19, 2016 | M | 35,874 | $26.99 | A | 177,964 | D | |
| Common StockF3 | Apr 19, 2016 | S | 35,874 | $100.016 | D | 142,090 | D | |
| Common Stock | Apr 19, 2016 | S | 4,126 | $100.00 | D | 137,964 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $26.99 | Apr 19, 2016 | M | 35,874 | D | — | Jul 30, 2018 | Common Stock | 35,874 | 64,126 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Options vest over a five year period with 20% vesting July 30, 2009, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on July 30, 2013.
- F3Sale prices reported for the transactions reported here range from $100.00 to $100.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.